NASDAQ: ATTOAttovia Therapeutics Inc Stock
$17.78-0.39 (-2.15%)
Updated Sep 25, 2026
ATTO Price
$17.78
Fair Value Price
$0.44
Market Cap
$811.68M
52 Week Low
$16.15
52 Week High
$28.00
P/E
N/A
P/B
-5.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.11
Operating Cash Flow
N/A
Beta
1.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ATTO Overview
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATTO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATTO
Ranked#333 of 464
Ranked#333 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.77 | A | |
| $7.75 | A | |
| $360.85 | A |
Be the first to know about important ATTO news, forecast changes, insider trades & much more!
ATTO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATTO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATTO ($17.78) is overvalued by 3,905.86% relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ATTO ($17.78) is not significantly undervalued (3,905.86%) relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATTO's short-term assets ($118.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more ATTO due diligence checks available for Premium users.
Valuation
ATTO fair value
Fair Value of ATTO stock based on Discounted Cash Flow (DCF)
Price
$17.78
Fair Value
$0.44
Overvalued by
3,905.86%
ATTO ($17.78) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATTO ($17.78) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATTO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-5.58x
Industry
5.19x
ATTO's financial health
Profit margin
Revenue
$450.0k
Net Income
-$20.7M
Profit Margin
-4,597.1%
Assets to liabilities
Assets
$128.3M
Liabilities
$15.6M
Debt to equity
-0.11
ATTO's short-term assets ($118.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATTO's short-term assets ($118.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATTO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATTO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.8M
Investing
$6.9M
Financing
-$556.0k
ATTO vs Biotech Stocks
Attovia Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.